



4th International Cancer Study & Bacteriology Conference

April 3-4, 2019 Philadelphia, USA

The Impact of γ -Irradiation on the Induction of Bystander Killing by Genetically Engineered Ovarian Tumor Cells: Implications for Clinical use as Cancer Vaccines

Jehad Zweiri* and Stephen Christmas
University of Liverpool, UK

Cellular based therapeutic approaches for cancer rely on careful consideration of finding the optimal cell to execute the cellular goal of cancer treatment. Cell lines and primary cell cultures have been used in some studies to compare the *in vitro* and *in vivo* efficacy of autologous vs allogeneic tumour cell vaccines. This study examines the effect of γ -irradiation on a range of tumor cell lines in conjunction with suicide gene therapy of cancer. To determine the efficacy of this modality, a series of *in vitro* and *in vivo* experiments were conducted using genetically modified and unmodified tumor cell lines. Following co-culture of HSV-TK modified tumor cells and unmodified tumor cells both *in vitro* and *in vivo* we observed that the PA-STK ovarian tumor cells were sensitive to γ -irradiation, completely abolishing their ability to induce bystander killing of unmodified tumor cells. In contrast, TK-modified human and mouse mesothelioma cells were found to retain their *in vitro* and *in vivo* bystander killing effect after γ -irradiation. Characterisation of tumor cell death showed that PA-STK cells underwent pyknosis (necrosis) after γ -irradiation. These results suggest that PA-STK cells are not suitable for clinical application of suicide gene therapy of cancer, as lethal γ -irradiation (100Gy) interferes with their bystander killing activity. However, the human mesothelioma cell line CRL-5830-TK retained its bystander killing potential after exposure to similarly lethal γ -irradiation (100Gy). CRL-5830 may therefore be a suitable vehicle for HSV-TK suicide gene therapy. This study highlights the diversity among tumor cell lines and the careful considerations needed to find the optimal tumor cell line for this type of whole cell tumour vaccination.

Biography:

Dr. Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor's degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the University of Liverpool Medical School and he is currently fellow of the British Higher Education Academy since 2012.